Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung
cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly …

Since the discovery of echinoderm microtubule-associated protein-like 4 (EML4) and
anaplastic lymphoma kinase (ALK) gene fusion in non-small cell lung carcinoma (NSCLC) …

Background Gene fusions represent promising targets for cancer therapy in lung cancer.
Reliable detection of multiple gene fusions is therefore essential. Methods Five …

Anaplastic lymphoma kinase (ALK) can be driven to oncogenic activity by different types of
mutational events such as point‐mutations, for example F1174L in neuroblastoma, and …

Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …

Tyrosine kinase inhibitors currently confer the greatest survival gain for nonsmall cell lung
cancer (NSCLC) patients with actionable genetic alterations. Simultaneously, the increasing …

Variants of the oncogenic EML4‐ALK fusion protein contain a similar region of ALK
encompassing the kinase domain, but different portions of EML4. Here, we show that EML4 …

Simple Summary Lung cancer is still one of the most commonly diagnosed and deadliest
cancers in the world. Its diagnosis at an early stage is highly necessary and will improve the …

Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a
model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher …

Based on superior efficacy and tolerability, targeted therapy is currently preferred over
chemotherapy and/or immunotherapy for actionable gene fusions that occur in late‐stage …